Table 6.
CpG | Position | Gene | Joubert et al. 2012 | MACHS | WakeMed SMKE | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
MoBa (450K) | NEST (450K) | WGBS | EPIC | |||||||||
Percent meth. diff. | p-Value | Percent meth. diff. | p-Value | Percent meth. diff. | p-Value | a | Ave. coverage | Percent meth. diff. | p-Value | |||
cg10399789 | Chr1:92945668 | GFI1 | 0.02 | 0.44 | 0.44 | 5.9 | 0.44 | |||||
cg09662411 | Chr1:92946132 | GFI1 | 6.8 | 0.26 | 0.78 | 3.3 | 0.61 | |||||
cg06338710 | Chr1:92946187 | GFI1 | 0.57 | 0.66 | 4.0 | 0.39 | ||||||
cg18146737 | Chr1:92946700 | GFI1 | 0.8 | 0.66 | 0.64 | 4.3 | 0.03 | |||||
cg12876356 | Chr1:92946825 | GFI1 | 0.15 | 0.43 | 5.1 | 0.01 | ||||||
cg18316974 | Chr1:92947035 | GFI1 | 0.50 | 0.54 | 3.9 | 0.12 | ||||||
cg09935388b | Chr1:92947588 | GFI1 | NA | NA | NA | NA | ||||||
cg14179389 | Chr1:92947961 | GFI1 | 0.43 | 0.74 | 4.1 | |||||||
cg23067299c | Chr5:323907 | AHRR | 3.2 | 3.7 | 10.3 | 0.07 | 0.63 | 8.1 | NA | NA | ||
cg03991871c | Chr5:368447 | AHRR | 0.07 | 0.52 | 0.86 | 8.2 | NA | NA | ||||
cg05575921 | Chr5:373378 | AHRR | 0.79 | 7.3 | ||||||||
cg21161138 | Chr5:399360 | AHRR | 0.99 | 9.3 | 0.01 | |||||||
cg11715943 | Chr6:33091841 | HLA-DPB2 | 0.80 | 1.7 | 0.69 | 0.96 | 7.8 | 1.2 | 0.11 | |||
cg19089201 | Chr7:45002287 | MYO1G | 1.4 | 2.2 | 0.6 | 0.71 | 0.43 | 3.5 | 0.4 | 0.05 | ||
cg22132788c | Chr7:45002486 | MYO1G | 2.8 | 2.1 | 4.3 | 0.81 | 0.42 | 2.6 | NA | NA | ||
cg04180046 | Chr7:45002736 | MYO1G | 5.3 | 4.9 | 0.80 | 0.69 | 1.9 | 2.7 | 0.01 | |||
cg12803068 | Chr7:45002919 | MYO1G | 8.3 | 3.8 | 0.0 | 0.97 | 0.92 | 3.5 | 0.7 | 0.03 | ||
cg04598670 | Chr7:68697651 | ENSG00000225718 | 0.96 | 10.3 | 0.89 | |||||||
cg25949550 | Chr7:145814306 | CNTNAP2 | 1.1 | 0.73 | 0.61 | 10.6 | ||||||
cg03346806 | Chr8:119157879 | EXT1 | 0.12 | 5.8 | 0.21 | 0.81 | 6.9 | 0.6 | 0.17 | |||
cg18655025 | Chr14:91008005 | TTC7B | 0.27 | 6.0 | 0.21 | 0.82 | 9.0 | 0.24 | ||||
cg05549655 | Chr15:75019143 | CYP1A1 | 3.5 | 3.8 | 1.9 | 0.90 | 7.6 | 3.9 | ||||
cg22549041 | Chr15:75019251 | CYP1A1 | 7.2 | 8.9 | 0.07 | 0.98 | 7.8 | 4.9 | 0.41 | |||
cg11924019 | Chr15:75019283 | CYP1A1 | 3.2 | 5.3 | 0.57 | 0.98 | 8.2 | 1.3 | 0.68 | |||
cg18092474 | Chr15:75019302 | CYP1A1 | 5.9 | 5.3 | 0.37 | 0.99 | 7.9 | 5.1 | 0.22 | |||
cg12477880 | Chr21:36259241 | RUNX1 | 4.6 | 4.0 | 0.09 | 3.2 | 0.21 | 0.98 | 8.1 | 1.6 | 0.21 |
Note: Twenty-six CpGs have previously been identified as differentially methylated (after adjusting for multiple testing using the Bonferroni correction) in whole cord blood by maternal tobacco smoke exposure in two study populations (MoBa and NEST), evaluated by Joubert et al. 2012, and have been widely replicated in subsequent studies. Look-up analyses were therefore conducted for these CpGs in both MACHS and the SMKE study. Percent methylation differences and raw p-values are presented for each CpG by study. False discovery rate-adjusted p-values are also presented for MACHS. Chr, chromosome; FDR, false discovery rate; MACHS, Maternal and Child Health Study; MoBa, Norwegian Mother and Child Cohort Study; NEST, Newborn Epigenetics Study; WGBS, whole-genome bisulfite sequencing.
Raw p-values from RADmeth beta-binomial regression models were adjusted for correlations with neighboring CpGs, as described previously (Dolzhenko and Smith 2014), and were subsequently adjusted for multiple testing using the Benjamini-Hochberg method to control the false discovery rate.
Since all reads in the exposed and unexposed group were methylated in MACHS, RADMeth did not calculate a p-value for this CpG.
These CpGs are not represented on the Infinium EPIC array and therefore could not be examined in the SMKE study.